RT @AurelieRheumo: BE OPTIMAL Phase 3 RCT Bimekizumab dual IL17A & F inhibitor in bionaive PsA âï¸ACR50 wk 16
Tweet Content
BE OPTIMAL Phase 3 RCT
Bimekizumab dual IL17A & F inhibitor in bionaive PsA
⭐️ACR50 wk 16 43.9% vs 10% PBO
⭐️PASI 90 wk 16 61% vs. 3% PBO
⭐️separation from wk 4
Safety: fungal injections BKZ > ADA
@RheumNow
LB0001 #EULAR2022 https://t.co/7ZwV1XDSNb
Show on Archive Page
On
Display in Search Results
On
PDQ
Off